Ménière’s Disease
Ménière's disease is highly variable and without a cure. Diet and medical therapy manage Ménière's disease symptoms in some patients. Meniett therapy may be used as a safe and effective second-line treatment.1-12 If these conservative treatments fail, surgical or destructive therapy may be needed.
About Ménière’s Disease Treatments
Detail – Ménière’s disease treatment often begins with lower risk therapies to manage symptoms before employing invasive or destructive surgery
Ménière's disease is an idiopathic, complex inner ear disorder that has no cure. Ménière's disease progresses differently in each patient, and not every patient responds to the same approach. For some, Ménière’s disease will improve with or without treatment. For others, symptoms of Ménière’s disease will progressively worsen.
Generally, the treatment goal is to manage Ménière's disease symptoms at an acceptable level using the most conservative method. Many physicians follow the Ménière's disease treatment ladder, trying lower risk therapies for Ménière's disease before more invasive or destructive surgery.1
There is much research on Ménière's disease and its treatments. We encourage physicians and patients to further their knowledge and understanding of this complicated disorder.
Functionality and Quality of Life in Ménière's Disease
Detail – AAO-HNS Ménière’s Disease Functional Level Scale14
Functionality level is an important indicator of a Ménière's disease patient's quality of life. Ménière’s disease symptoms are often unpredictable, and some Ménière's disease patients experience sudden vertigo attacks so severe that they live in constant fear of another attack. This can be very disabling for Ménière's disease patients, significantly reducing quality of life.13
The AAO-HNS has a self-assessed, six-point functional level scale that can help you determine the effect of vertigo symptoms on your Ménière's disease patients.14
Download the AAO-HNS Functional Level Scale.
Diet/Lifestyle and Medical Therapy
Diet/lifestyle and medical therapy is a first-level treatment for Ménière's disease that is usually prescribed before other Ménière's disease therapies. For some patients, this Ménière's disease therapy effectively manages their symptoms and no other treatments are necessary. This therapy may include a combination of:
- A low-sodium diet, diuretic therapy, and fluid intake regulation – designed to reduce excess endolymphatic fluid by reducing overall fluid levels in the body15-17
- Avoiding stress, tobacco, alcohol, and caffeine – known to exacerbate Ménière's disease symptoms15-17
- Prescription medications – may include steroids, antidepressants, antihistamines, anti-vertigo and vasoactive drugs, as well as other medications15-17
We offer information for patients about this Ménière's disease therapy, including tips for monitoring salt intake and website links to other resources.
Meniett Micropressure Therapy
Medtronic’s Meniett® device offers a second-level treatment that is safe, simple, and effective for managing the dizziness and vertigo symptoms of Ménière’s disease.1-12 The Meniett device:
- Has been developed and tested in nearly 30 years of clinical research in the US and abroad, including placebo-controlled studies1-12,18-22
- Is a small, portable micropressure therapy system, a type of treatment supported by the AAO-HNS for certain cases of Ménière’s disease, especially after diet/lifestyle and medical therapy fails23
- Is easy and convenient for Ménière’s disease patients to use just about anywhere
- Is most effective for patients whose worst symptom is vertigo, often the most debilitating effect of Ménière’s disease
Once they begin Meniett therapy, most patients know within 6 weeks if their Ménière's disease will respond to this treatment. A small number of patients don't respond, so Medtronic offers a full refund if the device is returned within the 6-week trial period. If Meniett therapy is discontinued, other Ménière's disease treatments can still be employed.
You can send your patients to Meniett.com to learn more about Ménière's disease, the Meniett device, and other Ménière's disease treatments.
Surgical and/or Destructive Therapy
Surgical and/or destructive therapy is considered a third-level treatment for Ménière's disease. These therapies offer varying levels of effectiveness but are more invasive procedures with higher risk. Destructive therapies that destroy some or all of the inner ear’s auditory and vestibular functions are irreversible.
Many Ménière's disease patients prefer to avoid more invasive surgical or destructive treatments, so they’re usually suggested only after more conservative Ménière’s disease therapies have failed. Surgical or destructive Ménière’s disease treatments include:
- Endolymphatic sac surgery – may include implanting a shunt in the affected ear to drain excess endolymphatic fluid or surgically “damaging” the endolymphatic sac
- Vestibular neurectomy – vestibular nerve section in the affected ear
- Labyrinthectomy – surgical removal of the labyrinth that permanently destroys the hearing and balance functions of the operated ear; usually only performed if most of the patient’s hearing in that ear is already lost
- Intratympanic injections (chemical labyrinthectomy) – ototoxic gentamicin or corticosteroids are injected through the eardrum into the middle ear space of the affected ear
Information for patients about surgical and/or destructive therapy for Ménière's disease is available also on this website.
References
- Dornhoffer JL, King D. The effect of the Meniett device in patients with Ménière's disease: long-term results. Otol Neurotol 2008; 29(6):868-74.
- Mattox DE, Reichert M. Meniett device for Ménière's disease: use and compliance at 3 to 5 years. Otol Neurotol 2008; 29(1):29-32.
- Weining H, Fang L, Bo G, Jinmei Z. Clinical long-term effects of Meniett pulse generator for Ménière's disease. Acta Otolaryngol 2009; 129(8): 819-825.
- Barbara M, Monini S, Chiappini I, Filipo R. Meniett therapy may avoid vestibular neurectomy in disabling Ménière's disease. Acta Otolaryngol 2007; 127(11):1136-1141.
- Nabi S, Parnes LS. Bilateral Ménière’s disease. Curr Opin Otolaryngol Head Neck Surg 2009; 17:356-362.
- Thomsen J, Sass K, Ödkvist L, Arlinger S. Local over-pressure treatment reduces vestibular symptoms in patients with Ménière’s disease: a clinical, randomized, multicenter, double-blind, placebo-controlled study. Otol Neurotol 2005; 26:68-73.
- Rajan GP, Din S, Atlas MD. Long-term effects of the Meniett device in Ménière’s disease: the Western Australian experience. J Laryngol Otol 2005; 119:391-395.
- Densert B, Sass K. Control of symptoms in patients with Ménière’s disease using middle ear applications: A two-year follow-up. Acta Otolaryngol 2001; 121(5):616-621.
- Gates GA, Green Jr. JD, Tucci DL, Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Ménière’s disease. Arch of Oto – HNS 2004; 130(6):718-725.
- Gates GA, Verrall A, Green Jr. JD, Tucci DL, Telian SA. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006; 132:1311-1316.
- Ödkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallquist J. Effects of middle ear pressure changes on clinical symptoms in patients with Ménière’s disease: A clinical, multicenter, placebo-controlled study. Acta Otolaryngol Suppl 2000; 543: 99-101.
- Densert B, Densert O, Arlinger S, Sass K, Ödkvist LM. Immediate effects of middle ear pressure changes on the electrocochleographic recordings in patients with Ménière’s disease: A clinical placebo-controlled study. 1997; Am J Otol 1997; 18:726-733.
- Anderson JP, Harris JP. Impact of Ménière’s disease on quality of life. Otol Neurotol 2001; 22:888-894.
- Monsell EM, et al. Committee on Hearing and Equilibrium of the American Academy of Otolaryngology–Head and Neck Surgery: Guidelines for the Diagnosis and Evaluation of Therapy in Ménière’s Disease. Otolaryngol Head Neck Surg 1995; 113(3): 181-185.
- Torok N. Old and new in Ménière’s disease. Laryngoscope. 1977; 87(11):1870-1877.
- Schuknecht HF. Pathophysiology of Ménière’s disease. Otolaryngol Clin North Am 1975; 8(2):507-514.
- American Hearing Research Foundation: Ménière's Disease. Accessed February 10, 2011.
- Densert B, Densert O. Overpressure in treatment of Ménière’s disease. Laryngoscope 1982; 92:1285-1292.
- Densert B. Effects of overpressure on hearing function in Ménière’s disease. Acta Otolaryngol (Stockh) 1987; 103:32-42.
- Feijen RA, Segenhout JM, Wit HP, Albers FWJ. Monitoring inner ear pressure changes in normal guinea pigs induced by the Meniett 20. Acta Otolaryngol 2000; 804-809.
- Densert B, Sass K, Arlinger S. Short-term effects of induced middle ear pressure changes on the electrocochleogram in Ménière’s disease. Acta Otolaryngol (Stockh) 1995; 115: 732-737.
- Committee on Equilibrium of the American Academy of Otolaryngology–Head and Neck Surgery: Micropressure Therapy Policy Statement. March 2008.

